We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

111 hedge funds and large institutions have $54.3M invested in Sanofi Contingent Value Rights in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

5% less capital invested

Capital invested by funds: $57M → $54.3M (-$2.79M)

3% less funds holding

Funds holding: 115111 (-4)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

56% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 16

Holders
111
Holders Change
-4
Holders Change %
-3.48%
% of All Funds
2.77%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
5
Increased
7
Reduced
16
Closed
7
Calls
Puts
Net Calls
Net Calls Change

GCVRZ Hedge Fund Activity: Q3 2017 in Review

111 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q3 2017, worth a combined $54.3M — down 4.9% from $57M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of GCVRZ and 5 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 7 added.

The largest buyer was Highbridge Capital Management, adding an estimated $239K. The largest seller was Bank of America, cutting an estimated $36.9K.

  • 111 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q3 2017, down from 115 in Q2 2017.
  • Funds reported $54.3M of Sanofi Contingent Value Rights stock for Q3 2017, down 4.9% quarter-over-quarter.
  • 5 funds opened new Sanofi Contingent Value Rights positions in Q3 2017 and 7 closed out, a net change of -2 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q3 2017 was Highbridge Capital Management, an estimated $239K added.
  • The largest Sanofi Contingent Value Rights seller in Q3 2017 was Bank of America, an estimated $36.9K sold.

Based on aggregated 13F filings for Q3 2017.